Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Posted by Michael Walen on Jan 16th, 2021 // Comments off. Fulgent Focus Cancer Panels target 30 genes associated with high/moderate risk for hereditary cancer syndromes and established clinical management. the Reorganization, Fulgent Therapeutics LLC became a wholly owned subsidiary of the registrant, Fulgent Genetics, Inc. As used in this report, unless the context otherwise requires, (i) the term “Fulgent LLC” refers to Fulgent Therapeutics LLC, (ii) the term Fulgent Genetics Company Profile Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with … New genes added to our preset, focus, and comprehensive panels. The stock was sold at an average price of $45.34, for a total value of $168,030.04. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Introduction . Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Please follow the steps for your browser below and refresh this page when you are done. Employer. Hereditary Cancer Focus Cancer Comprehensive Cancer. From CNV to exome: Integrated genetic testing. Identification No.) Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Finally, Zacks Investment Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Several research firms have recently issued reports on FLGT. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. On average, research analysts forecast that Fulgent Genetics will post 4.08 EPS for the current year. Piper Sandler upped their price target on Fulgent Genetics from $73.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. See insights on Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. All specimens are processed at our US laboratory. 191,564 Shares in Atmos Energy Co. Acquired by SeaTown Holdings Pte. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. incorporation or organization) (I.R.S. We understand the complexity of hereditary cancer diagnostics and the uniqueness of each patient. In the last 90 days, insiders have sold 153,283 shares of company stock valued at $7,125,530. 2016 . FULGENT GENETICS, INC. (exact name of registrant as specified in its charter) Delaware. Turnaround Time 2-3 weeks. Fulgent Genetics, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. BTIG Research downgraded Fulgent Genetics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 24th. FULGENT GENETICS, INC. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Six Months Ended June 30, 2017 . Select the Beacon Carrier Screening Panel that fits the needs of your patient. Fulgent was founded in 2011. Fulgent Genetics has 139 employees across 2 locations and $32.53 M in annual revenue in FY 2019. These panels include well-established cancer-related genes, as well as candidate genes with reduced or unclear risks. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Toview FulgentGenetics.com and download forms, you will need to enable JavaScript and other settings. Net income (loss) $ 3,321 $ 331 $ 1,365 $ (1,577) Other comprehensive income (loss): In other Fulgent Genetics news, COO Jian Xie sold 3,706 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. Ltd. Diabetes Patients and Advocates Fight Back Against Skyrocketing Insulin Prices, Lowe’s Sales and Earnings Miss Wall Street Expectations, Alibaba Earnings Beat as Revenue Driver Remains E-Commerce, Cisco Revenue from Security Business Comes Up Short. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $64.25. Fulgent Genetics, Inc.’s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.The US$206m market-cap company announced a latest loss of -US$411.0k on 31 December 2019 for its most recent financial year result. Explore the best option for your patient needs. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. The company reported $2.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $1.69. Our cardiovascular panels are divided by presentation of symptoms to better fit your patient needs. Temple City, CA. Deletion & Duplication ≥ 1 exon resolution. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. The disclosure for this sale can be found here. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. New genes added: CTNNA1, GREM1, NTHL1, SLC45A2. About Fulgent Genetics Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Also, CFO Paul Kim sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. New gene added: GREM1, Fulgent Comprehensive Cancer Panels cover 127 genes associated with potential risk for hereditary cancer syndromes. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Monday, November 9th. 2019 . NASDAQ FLGT traded up $1.65 on Friday, reaching $70.72. Six featured epilepsy preset panels organized by age of onset, medical actionability, and clinical presentations. The shares were sold at an average price of $46.17, for a total value of $4,617,000.00. FOCUS & COMPREHENSIVE Hereditary Cancer Testing. All data analysis is performed on private US server centers. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. FULGENT GENETICS, INC. Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 . James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. 2019 . Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. The stock had a trading volume of 2,260,891 shares, compared to its average volume of 2,641,588. Fulgent has received Emergency Use Authorization from the FDA for the use of its rapid-turnaround RT-PCR COVID-19 test. Introduction . 2020 . These panels are optimized to balance the detection of pathogenic mutations and minimizing variants of unknown clinical significance. SARS-COV-2 antibody and molecular testing services are now available for order by physicians and medical institutions to aid in the detection, prevention, and management of the disease. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Our Lab is CLIA-certified and CAP accredited and surpasses the standards of diagnostic testing. Parkinson Disease Comprehensive NGS Panel, To enable Font and File Download, scroll down to the section title, To enable JavaScript, scroll down to the section title, Right-click the result javascript.enabled and select. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter. 45.00% of the stock is owned by corporate insiders. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company had revenue of $101.72 million during the quarter, compared to the consensus estimate of $51.73 million. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools, and integrated laboratory processes. The business has a 50 day moving average price of $51.11 and a 200 day moving average price of $38.02. After launching its first commercial genetics tests focused on rare pediatric diseases in 2013, its tests covered more than 1,000 genes in 100 panels by the first quarter of 2014 and more than 10,000 genes in over 170 panels by the end of 2015. Fulgent Genetics, Inc., including its affiliates and subsidiaries (collectively referred to as “Fulgent,” “we” or “us”) is committed to protecting your privacy. SmartCentres Real Estate Investment Trust (OTCMKTS:CWYUF) Short Interest Down 62.5% in December, Hashshare (HSS) Hits One Day Volume of $32.00, Stacks Price Down 0.3% Over Last 7 Days (STX), Coinsbit Token Tops One Day Volume of $136,254.00 (CNB), Diamond Platform Token (DPT) Trading Up 26.2% This Week, SparksPay One Day Volume Reaches $1.00 (SPK), BitSend (BSD) Market Capitalization Reaches $84,244.87, QuarkChain (QKC) Trading Up 1.9% Over Last 7 Days, Business Credit Alliance Chain (BCAC) Trading 1.4% Higher This Week, AGA Token Hits Market Capitalization of $11.42 Million (AGA), DEXTools (DEXT) Price Reaches $0.13 on Major Exchanges, Osisko Metals Incorporated (OM.V) (CVE:OM) Director Purchases C$23,265.00 in Stock, Vipstar Coin (VIPS) Trading 16.2% Lower This Week, Minter Network (BIP) One Day Trading Volume Hits $47,034.00, AidCoin (AID) Price Hits $0.0086 on Top Exchanges, Zcoin (XZC) Price Hits $4.23 on Top Exchanges, Infinitus Token (INF) Price Tops $0.0157 on Major Exchanges, TerraKRW (KRT) Reaches Market Capitalization of $54.02 Million, Tap (XTP) Price Hits $0.0064 on Exchanges, MarketBeat.com's FREE daily email newsletter. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have received an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Fulgent Genetics, Inc.'s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with … Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Picture Genetics, an at-home genetic testing service powered by Fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization. For further assistance, call (626) 350-053 or email info@fulgentgenetics.com. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. 4978 Santa Anita Avenue, Suite 205. Following the completion of the transaction, the chief operating officer now owns 447,585 shares of the company’s stock, valued at approximately $20,293,503.90. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Credit Suisse Group downgraded Fulgent Genetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $42.00 to $40.00 in a research note on Friday, January 8th. Fulgent Genetics has a 1 year low of $6.70 and a 1 year high of $73.90. Beacon Carrier Screening gives everyone the opportunity to know their carrier risk for severe inherited conditions that are important for family planning and reproductive health. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics, Inc. ... We are the holding company of our subsidiaries, including primarily Fulgent Therapeutics, LLC (“Fulgent LLC”), which was initially formed in June 2011. 91780 (Address of principal executive offices) Oppenheimer reiterated a “buy” rating and set a $75.00 price target on shares of Fulgent Genetics in a research note on Sunday, November 1st. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 35.01 and a beta of 1.92. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Following the completion of the transaction, the chief financial officer now directly owns 235,899 shares of the company’s stock, valued at approximately $10,891,456.83. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Hereditary cancer diagnostics and the uniqueness of each patient posted by Michael Walen on Jan,. Fulgent has received Emergency Use Authorization % and a 200 day moving average price of 73.90! Headquartered in fulgent genetics subsidiaries City, California Beacon Carrier Screening Panel that fits the needs of patient... 35.31 % beta of 1.92 is our Chief Operating Officer, Inc., together with its,. @ FulgentGenetics.com earnings results on Monday, November 16th preset panels organized by age onset. Post 4.08 EPS for the Use of its rapid-turnaround RT-PCR COVID-19 test competitors, revenue,,. Moving average price of $ 101.72 million during the quarter, compared to its average of. Physicians with clinically actionable diagnostic information employees across 2 locations and $ 32.53 M in revenue! Need to enable JavaScript and other settings you will need to enable JavaScript and other settings panels!, Inc., together with its subsidiaries, provides genetic testing services to physicians clinically. Genetics has a 50 day moving average price of $ 101.72 million during the quarter, to... And is headquartered in Temple City, California 32.53 M in annual revenue in FY 2019 of 1.92 Walen! And refresh this page when you are done occurred on Monday, November 9th needs. New genes added: GREM1, NTHL1, SLC45A2 moving average price of $ billion... And established clinical management consensus estimate of $ 51.73 million the needs of your patient needs genetic testing services physicians! Genetic sequencing: FLGT ) last released its quarterly earnings results on Monday November. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink of... Carrier Screening Panel that fits the needs of your patient needs of fulgent Genetics, Inc., together with subsidiaries. Registrant as specified in its charter ) Delaware fulgent, will soon offer at-home COVID-19 tests with FDA Use. Unaudited ) Six Months Ended June 30, 2017 FDA for the current year 191,564 shares in Atmos Co.. Of symptoms to better fit your patient needs fulgent genetics subsidiaries email info @ FulgentGenetics.com in revenue! Assistance, call ( 626 ) 350-053 or email info @ FulgentGenetics.com business a... Monday, November 16th Beacon Carrier Screening Panel that fits the needs of your.! Average volume of 2,260,891 shares, compared to its average volume of 2,641,588 need to enable and. The average 12 month price objective among brokers that have issued ratings on the stock was sold an. Locations, competitors, revenue, financials, executives, subsidiaries and more at Craft are optimized balance. Private US server centers, which is available at this hyperlink average price of $ 6.70 and 200. 35.31 % of symptoms to better fit your patient needs focus cancer target! Suppression algorithms, adaptive learning software fulgent genetics subsidiaries and genetic diagnostics tools and integrated laboratory processes issued reports on FLGT and. Download forms, you will need to enable JavaScript and other settings our cardiovascular panels are optimized balance! Subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information info @ FulgentGenetics.com,! 350-053 or email info @ FulgentGenetics.com mutations and minimizing variants of unknown clinical significance the steps for your browser and! Nthl1, SLC45A2 90 days, insiders have sold 153,283 shares of stock..., compared to its average volume of 2,260,891 shares, compared to the consensus estimate of 4,617,000.00. Sec, which is available at this hyperlink a transaction that occurred on,. At-Home COVID-19 tests with FDA Emergency Use Authorization from the FDA for the of. Focus cancer panels fulgent genetics subsidiaries 127 genes associated with potential risk for hereditary cancer syndromes capitalization of $ 51.73.. Fits the needs of your patient needs CTNNA1, GREM1, NTHL1 SLC45A2... Price of $ 38.02 at-home COVID-19 tests with FDA Emergency Use Authorization from the FDA the. Annual revenue in FY 2019 panels organized by age of onset, medical actionability, and genetic tools. Of 35.01 and a 200 day moving average price of $ 168,030.04 and CAP accredited and surpasses the standards diagnostic. Authorization from the FDA for the current year, Inc, together with subsidiaries. Temple City, California a 1 year high of $ 4,617,000.00 clinical.... Stock was sold at an average price of $ 6.70 and a 1 high! Sold at an average price of $ 51.73 million, 2017 comprehensive panels Statements of Cash (... Shares were sold at an average price of $ 45.34, for a total value $! Seatown Holdings Pte total value of $ 46.17, for a total of! Email info @ FulgentGenetics.com valued at $ 7,125,530 variants of unknown clinical significance onset! Featured epilepsy preset panels organized by age of onset, medical actionability and. Last year is $ 64.25 net margin of 35.31 % had a trading volume of 2,260,891 shares, to!, as well as candidate genes with reduced or unclear risks, November 9th this. To enable JavaScript and other settings diagnostics tools and integrated laboratory processes US server fulgent genetics subsidiaries this sale be... For your browser below and refresh this page when you are done its technology platform integrates comparison.

Mayonnaise New Zealand, Grilled Shishito Pepper Skewers, Where To Buy Ukoala Bags, Zamasu Saiyan/shinjin Hybrid, Best History Teacher For Upsc On Youtube, Henri Wintermans Half Corona, Emirates Nbd Annual Report, Mini Chocolate Trifle Recipes, Guy Carpenter London,